74 studies found for:    pertuzumab
Show Display Options
Rank Status Study
1 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
2 Active, not recruiting Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Conditions: Neuroendocrine Carcinoma;   Neuroendocrine
Interventions: Drug: Bevacizumab;   Drug: Pertuzumab;   Drug: Sandostatin LAR® Depot
3 Not yet recruiting Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Malignant Tumor of the Breast
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
4 Active, not recruiting Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: pertuzumab;   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Other: immunohistochemistry staining method;   Other: fluorescence in situ hybridization;   Other: gene expression analysis;   Other: mutation analysis;   Other: polymerase chain reaction;   Other: laboratory biomarker analysis
5 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
6 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
7 Recruiting Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Condition: Her2-Positive Breast Cancer
Interventions: Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: 5-fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
8 Active, not recruiting Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
9 Recruiting Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Condition: HER2-positive Metastatic Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: T-DM1
10 Recruiting Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Condition: Breast Neoplasms
Interventions: Drug: Trastuzumab;   Drug: pertuzumab;   Drug: lapatinib
11 Recruiting Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Positron emission tomography (PET);   Drug: Trastuzumab;   Drug: Pertuzumab
12 Recruiting Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC)
Condition: Breast Cancer
Intervention: Other: 111In-Pertuzumab + SPECT-CT
13 Completed
Has Results
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Pertuzumab;   Drug: Erlotinib
14 Recruiting Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Trastuzumab;   Drug: Pertuzumab
15 Completed
Has Results
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Biological: pertuzumab;   Biological: Trastuzumab emtansine [Kadcyla]
16 Active, not recruiting A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: capecitabine;   Drug: cisplatin;   Drug: pertuzumab;   Drug: trastuzumab
17 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
18 Terminated A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Adrenal Gland Tumors;   Neuroblastoma;   Pancreatic Neuroendocrine Tumors;   Multiple Endocrine Neoplasia
Interventions: Drug: pertuzumab;   Drug: erlotinib
19 Recruiting Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Pertuzumab, Trastuzumab and Eribulin
20 Terminated A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Condition: Pancreatic Cancer
Interventions: Drug: Pertuzumab;   Drug: Erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years